Treatment of Anemia with Darbepoetin Alfa in Patients with Low and Intermediate-1 Risk Myelodysplastic Syndromes. Results from the ARAMYS Study

被引：1

作者：

Villegas, Ana ^{[1
]}

Arrizabalaga, B. ^{[2
]}

Fernandez-lago, C. ^{[3
]}

Mouzo, M. ^{[4
]}

Mayans, Jr ^{[5
]}

Gonalez-Porras, Jr ^{[6
]}

Duarte, Rafael ^{[7
]}

Remacha, Angel Francisco ^{[8
]}

Luno, Elisa ^{[9
]}

Gasquet, J. A.

机构：

[1] Hosp Clin San Carlos, Madrid, Spain

[2] Hosp Cruces, Dept Haematol, Bilbao, Spain

[3] Hosp Juan Canalejo, Dept Haematol, La Coruna, Spain

[4] Complejo HU Vigo Xeral Cies, Dept Haematol, Vigo, Spain

[5] Hosp Arnau Vilanova, Dept Haematol, Valencia, Spain

[6] Hosp Univ Salamanca, Salamanca, Spain

[7] Hosp Duran & Reynals ICO, Bellvitge, Spain

[8] Hosp Santa Creu & Sant Pau, Barcelona, Spain

[9] Hosp Univ Cent Asturias, Oviedo, Spain

来源：

BLOOD | 2008年 / 112卷 / 11期

关键词：

D O I：

10.1182/blood.V112.11.3451.3451

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1184 / 1184

页数：1

共 50 条

[21] 5-AZACYTIDINE FOR THE TREATMENT OF LOW/INTERMEDIATE-1 IPSS RISK MYELODYSPLASTIC SYNDROMES: RESULTS IN 63 PATIENTS FROM THE ITALIAN PATIENT NAMED PROGRAM [J].

Musto, P. ;

Maurillo, L. ;

Spagnoli, A. ;

Gozzini, A. ;

Rivellini, F. ;

Tatarelli, C. ;

Lunghi, M. ;

Fili, C. ;

Orciuolo, E. ;

Ciuffreda, L. ;

Vigna, E. ;

Della Cioppa, P. ;

Ferrero, D. ;

Palmieri, S. ;

Palumbo, G. ;

Di Renzo, N. ;

Oliva, E. ;

Sanpaolo, G. ;

Pastore, D. ;

Tonso, A. ;

Santagostino, A. ;

Villani, O. ;

D'Auria, F. ;

D'Arco, A. ;

Gaidano, G. ;

Galimberti, S. ;

Russo, D. ;

Venditti, A. ;

Aloe-Spiriti, M. A. ;

Leone, G. ;

Santini, V. .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 :368-368

[22] Antithymocyte globulin for the treatment of patients with 'low risk' myelodysplastic syndromes. [J].

Killick, S ;

Marsh, JCW ;

Cavenagh, J ;

Mijovic, A ;

Mufti, G ;

Gordon-Smith, EC ;

Bowen, D .

BRITISH JOURNAL OF HAEMATOLOGY, 1999, 105 :69-69

[23] Antithymocyte globulin for the treatment of patients with 'low risk' myelodysplastic syndromes. [J].

Killick, SB ;

Marsh, JC ;

Cavenagh, JD ;

Mijovic, A ;

Mufti, G ;

Gordon-Smith, EC ;

Bowen, DT .

BLOOD, 1999, 94 (10) :306A-307A

[24] Darbepoetin alfa for treating anemia in patients with low-risk myelodysplastic syndromes: Exploratory analysis of baseline predictors of response. [J].

Gabrilove, J. ;

Paquette, R. ;

Lyons, R. ;

Mushtaq, C. ;

Sekeres, M. ;

Lam, H. ;

Dreiling, L. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) :356S-356S

[25] ACE-536 INCREASES HEMOGLOBIN LEVELS IN PATIENTS WITH LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES (MDS): PRELIMINARY RESULTS FROM A PHASE 2 STUDY [J].

Platzbecker, U. ;

Germing, U. ;

Giagounidis, A. ;

Goetze, K. ;

Kiewe, P. ;

Mayer, K. ;

Ottmann, O. ;

Radsak, M. ;

Wolff, T. ;

Hankin, M. ;

Wilson, D. ;

Sherman, M. ;

Attie, K. .

HAEMATOLOGICA, 2014, 99 :500-500

[26] LUSPATERCEPT INCREASES HEMOGLOBIN AND REDUCES TRANSFUSION BURDEN IN PATIENTS WITH LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES (MDS): PRELIMINARY RESULTS FROM A PHASE 2 STUDY [J].

Platzbecker, U. ;

Germing, U. ;

Giagounidis, A. ;

Goetze, K. ;

Kiewe, P. ;

Mayer, K. ;

Ottmann, O. ;

Radsak, M. ;

Wolff, T. ;

Haase, D. ;

Hankin, M. ;

Wilson, D. ;

Zhang, X. ;

Laadem, A. ;

Sherman, M. ;

Attie, K. .

LEUKEMIA RESEARCH, 2015, 39 :S25-S25

[27] EFFECT OF ERYTROPOIETIN-ALFA IN LOW AND INTERMEDIATE 1 RISK MYELODYSPLASTIC SYNDROMES WITH ANEMIA: ONE CENTER EXPERIENCE [J].

Ertop, S. ;

Aslaner, M. ;

Erol, B. ;

Ilikhan, S. ;

Bilici, M. .

LEUKEMIA RESEARCH, 2015, 39 :SS21-SS21

[28] Lenalidomide is active in Japanese patients with symptomatic anemia in low- or intermediate-1 risk myelodysplastic syndromes with a deletion 5q abnormality [J].

Hironori Harada ;

Mitsumasa Watanabe ;

Kenshi Suzuki ;

Soshi Yanagita ;

Takahiro Suzuki ;

Yataro Yoshida ;

Akiro Kimura ;

Mitsuru Tsudo ;

Akira Matsuda ;

Kaoru Tohyama ;

Masafumi Taniwaki ;

Kenichi Takeshita ;

Masaaki Takatoku ;

Keiya Ozawa .

International Journal of Hematology, 2009, 90 :353-360

[29] Lenalidomide is active in Japanese patients with symptomatic anemia in low- or intermediate-1 risk myelodysplastic syndromes with a deletion 5q abnormality [J].

Harada, Hironori ;

Watanabe, Mitsumasa ;

Suzuki, Kenshi ;

Yanagita, Soshi ;

Suzuki, Takahiro ;

Yoshida, Yataro ;

Kimura, Akiro ;

Tsudo, Mitsuru ;

Matsuda, Akira ;

Tohyama, Kaoru ;

Taniwaki, Masafumi ;

Takeshita, Kenichi ;

Takatoku, Masaaki ;

Ozawa, Keiya .

INTERNATIONAL JOURNAL OF HEMATOLOGY, 2009, 90 (03) :353-360

[30] Evaluation of VEGF and VEGFR gene expression as prognostic markers in low and intermediate-1 risk patients with myelodysplastic syndromes [J].

Kalitin, Nikolay ;

Dudina, Galina ;

Kostritsa, Natalia ;

Sivirinova, Anastasiya ;

Karamysheva, Aida .

ONCOLOGY LETTERS, 2023, 25 (03)

← 1 2 3 4 5 →